Streetbeat News

Analyst Ratings

MSFT

The article provides an in-depth comparison of Microsoft (NASDAQ:MSFT) against its peers in the Software industry, focusing on key financial metrics such as P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. Microsoft shows favorable growth potential with a lower P/E ratio than the industry average, potential undervaluation based on its P/B ratio, but a higher P/S ratio suggesting possible overvaluation. Its ROE is below the industry average, but it has significantly higher EBITDA and gross profit, indicating strong profitability and cash flow generation. Microsoft's revenue growth also outperforms the industry average.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 4:00 pm

CPT

Eight analysts have recently updated their ratings on Camden Prop Trust (NYSE:CPT), showing a mix of bullish and bearish perspectives. The average 12-month price target is now $106.12, down from $112.30, with a high estimate of $122.00 and a low of $95.00. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting changes in market dynamics and company performance. Camden Prop Trust, a real estate investment trust, has shown a revenue growth of 4.55% as of September 30, 2023, but has below-average net margin and ROE.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 4:00 pm

PANL

Pangaea Logistics Solutions' stock trades lower following a downgrade from Buy to Neutral by Alliance Global Partners.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:59 pm

VRTX

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is set to release its Q4 earnings on Feb. 5, 2024, with analysts predicting an EPS of $4.10, up from $3.76 year-over-year, and revenue of $2.51 billion, up from $2.3 billion. The company recently announced positive results from its Phase 3 trials for VX-548. Shares fell 2.1% to $424.68 recently. Analysts from JP Morgan, Truist Securities, Canaccord Genuity, RBC Capital, and HC Wainwright & Co. have updated their ratings and price targets for VRTX.

Portfolio Pulse from Avi Kapoor

February 05, 2024 | 3:59 pm

TT

Goldman Sachs analyst Joe Ritchie has maintained a Neutral rating on Trane Technologies (NYSE:TT) and increased the price target from $253 to $287.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:53 pm

OTIS

RBC Capital analyst Nicholas Housden reiterates an Outperform rating on Otis Worldwide (OTIS) and maintains a $100 price target.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:52 pm

TEVA

Goldman Sachs analyst Nathan Rich maintains a Neutral rating on Teva Pharmaceutical Industries (NYSE:TEVA) and raises the price target from $10 to $11.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:52 pm

JKS

JinkoSolar's stock price is trading lower following a downgrade by HSBC from Buy to Hold, along with a new price target of $30.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:52 pm

SAIA

Goldman Sachs analyst Jordan Alliger maintains a Neutral rating on Saia (NASDAQ:SAIA) and raises the price target from $398 to $446.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:51 pm

PTON

Goldman Sachs analyst Eric Sheridan has maintained a Neutral rating on Peloton Interactive (PTON) and reduced the price target from $6.5 to $5.75.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:49 pm